Results 161 to 170 of about 40,259 (213)

A primer on the methods of skeletal and cardiac muscle mechanics using permeabilized preparations. [PDF]

J Gen Physiol
Hessel AL, Manross KM, Borkowski MM, Rand CD, Nguyen K.   +4 more
europepmc   +1 more source

Cellular and Molecular Mechanisms of Heart Failure and Sudden Cardiac Death in Hypertrophic Cardiomyopathy and Methods Used for Their Pathogenetic Correction. [PDF]

Biomedicines
Kakturskiy L, Belov Y, Mikhaleva L, Lysenko A, Gioeva Z, Tikhonova N, Gutyrchik N.   +6 more
europepmc   +1 more source

Pediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future. [PDF]

Rev Cardiovasc Med
Das BB.
europepmc   +1 more source

Myosin Modulator Aficamten Inhibits Force by Altering Myosin's Biochemical Activity Without Changing Thick Filament Structure. [PDF]

JACC Basic Transl Sci
Mohran S, Kooiker KB, Naim A, Pilagov M, Asencio A, Turner KL, Ma W, Flint G, Jiang S, Zhao J, McMillen TS, Mandrycky C, Mahoney-Schaefer M, Irving TC, Tanner BCW, Kad NM, Regnier M, Moussavi-Harami F.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

FDA approves first cardiac myosin inhibitor

Nature Reviews Drug Discovery, 2022
openaire   +3 more sources

Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management

Annals of Pharmacotherapy, 2023
Objective: To review the current literature on the efficacy and safety of cardiac myosin inhibitors (CMIs) for the treatment of hypertrophic cardiomyopathy (HCM). Data Sources: A literature search was conducted on PubMed from origin to April 2023, using the search terms “MYK-461,” “mavacamten,” “CK-3773274,” and “aficamten.” Studies were limited to ...
Alyssa Sykuta, Connie H. Yoon, Sarah Baldwin, Natalie I. Rine, Michael Young, Adam Smith   +5 more
openaire   +2 more sources

Monitoring treatment with cardiac myosin inhibitors in symptomatic obstructive hypertrophic cardiomyopathy

Current Opinion in Cardiology, 2023
Purpose of review Cardiac myosin inhibitors (CMIs) represent a major milestone in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The objective of this review is to discuss the mechanisms of action, clinical trial evidence, safety profile and monitoring of CMIs, which are important to the ...
Safia, Chatur, Sheila M, Hegde
openaire   +2 more sources